NALIRIFOX in Combination With Camrelizumab for BRPC: a Prospective, Exploratory Study
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
National Health Research Institutes, Taiwan
University Hospital, Essen
Sun Yat-sen University
University of Cologne
Case Comprehensive Cancer Center
Sun Yat-sen University
National Cheng-Kung University Hospital
Fujian Cancer Hospital
Ludwig-Maximilians - University of Munich
GERCOR - Multidisciplinary Oncology Cooperative Group
Amphia Hospital
Shandong Cancer Hospital and Institute
Criterium, Inc.
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Cinnagen
National Cancer Institute, Naples
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Zhujiang Hospital
Zhujiang Hospital
Sixth Affiliated Hospital, Sun Yat-sen University
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Tanta University
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
University of Southern California
Vastra Gotaland Region
Sun Yat-sen University
Alliance for Clinical Trials in Oncology
Tarveda Therapeutics
First Affiliated Hospital of Wenzhou Medical University
Australasian Gastro-Intestinal Trials Group
CSPC Ouyi Pharmaceutical Co., Ltd.
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Tianjin Medical University Cancer Institute and Hospital
Khon Kaen University
West China Hospital
Shanghai Zhongshan Hospital
Centro Ricerche Cliniche di Verona
Sun Yat-sen University
Grupo Espanol Multidisciplinario del Cancer Digestivo
National Cancer Centre, Singapore
Blokhin's Russian Cancer Research Center
Blokhin's Russian Cancer Research Center
Sun Yat-sen University
Tianjin Medical University Cancer Institute and Hospital
Benaroya Research Institute
Shanghai JMT-Bio Inc.
Massachusetts General Hospital
Eastern Hepatobiliary Surgery Hospital